Idorsia Ltd (IDRSF) Price & Analysis

Compare

21 Followers

IDRSF Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.70 - $5.82

Previous CloseN/A

Volume601.00

Average Volume (3M)355.00

Market Cap

CHF1.37B

Enterprise Value$1.66B

Total Cash (Recent Filing)CHF82.16M

Total Debt (Recent Filing)CHF1.30B

Price to Earnings (P/E)―

Beta-0.08

Next Earnings

Oct 30, 2025

EPS Estimate

-0.28

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.00

Shares Outstanding236,338,610

10 Day Avg. Volume535

30 Day Avg. Volume355

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

CHF4.25

Price Target Upside-27.05% Downside

Rating ConsensusModerate Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Market EntryIdorsia's regional partner Simcere Pharmaceuticals Group Ltd. has launched QUVIVIQ™ (daridorexant) in China, marking its entry into the Chinese market.

Profitability PathThe latest financial guidance charts a path to profitability, driven principally by European and Canadian market uptake of its marketed anti-insomnia medication daridorexant.

Regulatory ApprovalSwissmedic has granted marketing authorization for JERAYGO™ (aprocitentan) for the treatment of resistant hypertension, marking an incremental advance for Idorsia.

Bears Say

Clinical RisksRisks include the failure of late-stage candidates in pivotal trials and inability to obtain timely approval of key assets.

Regulatory RisksRisks include failure of late-stage candidates in pivotal trials and inability to obtain timely approval of key assets.

Idorsia Ltd News

Idorsia upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju upgraded Idorsia (IDRSF) to Buy from Neutral with a price target of CHF...

25d ago

Idorsia’s Growth Potential Bolstered by Aprocitentan Approval and Strategic Commercialization Efforts

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Idorsia Ltd, with...

21d ago

Idorsia price target raised to CHF 2 from CHF 1 at Deutsche Bank

Deutsche Bank raised the firm’s price target on Idorsia (IDRSF) to CHF 2 from CHF 1 and keeps...

2M ago

Idorsia Ltd Earnings Call: Strong Growth Amid Challenges

Idorsia Ltd (($CH:IDIA)) has held its Q2 earnings call. Read on for the main highlights of the call....

2M ago

Idorsia Ltd Earnings Call: Balancing Challenges and Growth

Idorsia Ltd (($CH:IDIA)) has held its Q4 earnings call. Read on for the main highlights of the call....

7M ago

Idorsia upgraded to Hold from Sell at Deutsche Bank

Deutsche Bank analyst Emmanuel Papadakis upgraded Idorsia (IDRSF) to Hold from Sell with an unchanged price target of...

11M ago

Idorsia rating suspended at Goldman Sachs

Goldman Sachs analyst Rajan Sharma suspended the firm’s investment rating, price target and earnings estimates for Idorsia (IDRSF)...

12M ago

Idorsia price target lowered to CHF 1.20 from CHF 2 at JPMorgan

JPMorgan lowered the firm’s price target on Idorsia (IDRSF) to CHF 1.20 from CHF 2 and keeps a...

12M ago

Idorsia price target lowered to CHF 1 from CHF 4 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Idorsia to CHF 1 from CHF 4 and keeps an...

2y ago

Idorsia upgraded to Hold from Reduce at Kepler Cheuvreux

Kepler Cheuvreux upgraded Idorsia to Hold from Reduce with a CHF 1.80 price target. Published first on TheFly...

2y ago

Idorsia price target lowered by CHF 4.50 at JPMorgan

JPMorgan lowered the firm’s price target on Idorsia to CHF 2 from CHF 6.50 and keeps a Neutral...

2y ago

Idorsia downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded Idorsia to Neutral from Buy with a price target of CHF 2, down from CHF...

2y ago

IDRSF FAQ

What was Idorsia Ltd’s price range in the past 12 months?

Idorsia Ltd lowest stock price was $0.70 and its highest was $5.82 in the past 12 months.

What is Idorsia Ltd’s market cap?

Idorsia Ltd’s market cap is CHF1.37B.

When is Idorsia Ltd’s upcoming earnings report date?

Idorsia Ltd’s upcoming earnings report date is Oct 30, 2025 which is in 20 days.

How were Idorsia Ltd’s earnings last quarter?

Idorsia Ltd released its earnings results on Jul 30, 2025. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.248 by $0.248.

Is Idorsia Ltd overvalued?

According to Wall Street analysts Idorsia Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Idorsia Ltd pay dividends?

Idorsia Ltd does not currently pay dividends.

What is Idorsia Ltd’s EPS estimate?

Idorsia Ltd’s EPS estimate is -0.28.

How many shares outstanding does Idorsia Ltd have?

Idorsia Ltd has 236,338,610 shares outstanding.

What happened to Idorsia Ltd’s price movement after its last earnings report?

Idorsia Ltd reported an EPS of $0 in its last earnings report, beating expectations of -$0.248. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Idorsia Ltd?

Currently, no hedge funds are holding shares in IDRSF

Company Description

Idorsia Ltd

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

Idorsia Ltd (IDRSF) Earnings & Revenues

Historic Earnings Reports

IDRSF Stock 12 Month Forecast

Average Price Target

$4.25

▼(-27.05% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","-1":"-$1","1.25":"$1.25","3.5":"$3.5","5.75":"$5.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7.492086,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.49</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.2455154,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.497362,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.25,3.5,5.75,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.34,3.6593912307692307,3.9787824615384615,4.298173692307692,4.617564923076923,4.936956153846154,5.256347384615385,5.575738615384616,5.895129846153846,6.214521076923077,6.533912307692308,6.853303538461539,7.172694769230769,{"y":7.492086,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.34,3.4096550307692306,3.4793100615384613,3.548965092307692,3.6186201230769233,3.688275153846154,3.7579301846153847,3.8275852153846155,3.8972402461538462,3.9668952769230774,4.036550307692308,4.106205338461539,4.17586036923077,{"y":4.2455154,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.34,3.275181692307692,3.2103633846153845,3.1455450769230766,3.080726769230769,3.0159084615384613,2.951090153846154,2.886271846153846,2.8214535384615385,2.7566352307692306,2.691816923076923,2.626998615384615,2.5621803076923078,{"y":2.497362,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.59,"date":1725148800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.59,"date":1727740800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.09,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.92,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.85,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.75,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.05,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.86,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.4,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.59,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.34,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >